Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study
Nathalie Gaspar, Rajkumar Venkatramani, Stefanie Hecker‐Nolting, Soledad Gallego, Franco Locatelli, Francisco Bautista, Alessandra Longhi, Cyril Lervat, Natacha Entz‐Werlé, Michela Casanova, Isabelle Aerts, Sandra J. Strauss, Estelle Thébaud, Bruce Morland, Adela Cañete, Perrine Marec‐Bérard, Marion Gambart, Claudia Rössig, Chinyere E. Okpara, Cixin He, Lea Dutta, Quentin Campbell‐Hewson
Topics & Concepts
MedicineIfosfamideLenvatinibInternal medicineClinical endpointEtoposideTolerabilityOncologyPhases of clinical researchRefractory (planetary science)Febrile neutropeniaProgressive diseaseChemotherapySurgeryClinical trialNeutropeniaAdverse effectCancerPhysicsAstrobiologyThyroid cancerSarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsAngiogenesis and VEGF in Cancer